Full text is available at the source.
Abstract
mRNA vaccines may offer a transformative alternative for herpes zoster prevention due to their rapid manufacturing and favorable safety profile.
- Herpes zoster, caused by varicella-zoster virus, poses significant health risks, especially in older adults.
- Current vaccines, such as Shingrix, have limitations including high reactogenicity and complex manufacturing processes.
- mRNA vaccines allow for precise antigen design and quick production, which could overcome these limitations.
- Preclinical studies indicate promising immunogenicity of mRNA vaccine candidates against herpes zoster.
- Leading mRNA vaccine candidates are progressing into clinical trials, highlighting their potential in HZ prevention.
Simplified